Clinical value of 11C-methionine PET/CT in patients with plasma cell malignancy: Comparison with 18F-FDG PET/CT

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 40, Issue 5, 2013, Pages 708-715

  Nakamoto, Yuji ^a   Kurihara, Kensuke ^a   Nishizawa, Masatoshi ^a   Yamashita, Kouhei ^a   Nakatani, Koya ^a   Kondo, Tadakazu ^a   Takaori Kondo, Akifumi ^a   Togashi, Kaori ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Methionine .FDG .Multiplemyeloma; PET CT; Plasmacytoma

Indexed keywords

FLUORODEOXYGLUCOSE F 18; METHIONINE C 11; CARBON-11 METHIONINE; METHIONINE; DIAGNOSTIC AGENT;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; COMPARATIVE STUDY; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DRUG UPTAKE; FEMALE; HISTOLOGY; HUMAN; HYPERGAMMAGLOBULINEMIA; MALE; MAXIMUM STANDARDIZED UPTAKE VALUE; MIDDLE AGED; MULTIPLE MYELOMA; PET SCANNER; PLASMACYTOMA; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RADIOLOGICAL PARAMETERS; SENSITIVITY AND SPECIFICITY; VERY ELDERLY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; MULTIMODAL IMAGING; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; SCINTISCANNING; METHODOLOGY;

AGED; AGED, 80 AND OVER; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; METHIONINE; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASMS, PLASMA CELL; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84888398932     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-012-2333-3     Document Type: Article

References (27)

1. Delorme S, Baur-Melnyk A. Imaging in multiple myeloma. Eur J Radiol. 2009;70:401-8.
2. Walker RC, Brown TL, Jones-Jackson LB, De Blanche L, Bartel T. Imaging of multiple myeloma and related plasma cell dyscrasias. J Nucl Med. 2012;53:1091-101.
3. Stäbler A, Baur A, Bartl R, Munker R, Lamerz R, Reiser MF. Contrast enhancement and quantitative signal analysis in MR imaging of multiple myeloma: assessment of focal and diffuse growth patterns in marrow correlated with biopsies and survival rates. AJR Am J Roentgenol. 1996;167:1029-36.
4. Baur A, Stäbler A, Nagel D, Lamerz R, Bartl R, Hiller E, et al. Magnetic resonance imaging as a supplement for the clinical staging system of Durie and Salmon? Cancer. 2002;95:1334-45.
5. Baur-Melnyk A, Buhmann S, Dürr HR, Reiser M. Role of MRI for the diagnosis and prognosis of multiple myeloma. Eur J Radiol. 2005;55:56-63.
6. Walker R, Barlogie B, Haessler J, Tricot G, Anaissie E, Shaughnessy Jr. JD, et al. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol. 2007;25:1121-8.
7. Zamagni E, Nanni C, Patriarca F, Englaro E, Castellucci P, Geatti O, et al. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica. 2007;92:50-5.
8. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma. J Nucl Med. 2008;49:195-200.
9. van Lammeren-Venema D, Regelink JC, Riphagen II, Zweegman S, Hoekstra OS, Zijlstra JM. 18F-fluoro-deoxyglucose positron emission tomography in assessment of myeloma-related bone disease: a systematic review. Cancer. 2012;118:1971-81.
10. 18F-FDG PET/CT for detection and localization of residual or recurrent disease in patients with multiple myeloma after stem cell transplantation. Eur J Nucl Med Mol Imaging. 2012;39:493-500.
11. Durie BG, Waxman AD, D'Agnolo A, Williams CM. Whole-body (18)F-FDG PET identifies high-risk myeloma. J Nucl Med. 2002;43:1457-63.
12. Bartel TB, Haessler J, Brown TL, Shaughnessy Jr. JD, van Rhee F, Anaissie E, et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 2009;114:2068-76.
13. Zamagni E, Patriarca F, Nanni C, Zannetti B, Englaro E, Pezzi A, et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011;118:5989-95.
14. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36:842-54.
15. Dankerl A, Liebisch P, Glatting G, Friesen C, Blumstein NM, Kocot D, et al.Multiple myeloma: molecular imaging with 11C-methionine PET/CT - initial experience. Radiology. 2007;242:498-508.
16. NishizawaM, Nakamoto Y, Suga T, Kitano T, Ishikawa T, Yamashita K. (11)C-Methionine PET/CT for multiple myeloma. Int J Hematol. 2010;91:733-4.
17. Machida H, Shinohara T, Hino H, Yoshida M, Hatakeyama N, Okano Y, et al. Immunoglobulin D-lambda type multiple myeloma presenting with FDG-PET/CT negative bone marrow involvement. Intern Med. 2011;50:1483-7.
18. Shinozaki N, Uchino Y, Yoshikawa K, Matsutani T, Hasegawa A, Saeki N, et al. Discrimination between low-grade oligodendrogliomas and diffuse astrocytoma with the aid of 11C-methionine positron emission tomography. J Neurosurg. 2011;114:1640-7.
19. Terakawa Y, Tsuyuguchi N, Iwai Y, Yamanaka K, Higashiyama S, Takami T, et al. Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J Nucl Med. 2008;49:694-9.
20. Otto D, Boerner AR, Hofmann M, Brunkhorst T, Meyer GJ, Petrich T, et al. Pre-operative localisation of hyperfunctional parathyroid tissue with 11C-methionine PET. Eur J Nucl Med Mol Imaging. 2004;31:1405-12.
21. Beggs AD, Hain SF. Localization of parathyroid adenomas using 11C-methionine positron emission tomography. Nucl Med Commun. 2005;26:133-6.
22. 18F-FDG and 11C-methionine PET for evaluation of treatment response of lung cancer after stereotactic radiotherapy. Ann Nucl Med. 2004;18:669-74.
23. Schuster DM, Votaw JR, Nieh PT, Yu W, Nye JA, Master V, et al. Initial experience with the radiotracer anti-1-amino-3-18Ffluorocyclobutane- 1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med. 2007;48:56-63.
24. 18F-FDG. J Nucl Med. 2003;44:533-9.
25. Pauleit D, Stoffels G, Schaden W, Hamacher K, Bauer D, Tellmann L, et al. PET with O-(2-18F-fluoroethyl)-L-tyrosine in peripheral tumors: first clinical results. J Nucl Med. 2005;46:411-6.
26. Isoda A, Higuchi T, Nakano S, Arisaka Y, Kaira K, Kamio T, et al. (18)F-FAMT in patients with multiple myeloma: clinical utility compared to (18)F-FDG. Ann Nucl Med. 2012;26:811-6.
27. Nakamoto Y, Cohade C, Tatsumi M, Hammoud D, Wahl RL. CT appearance of bone metastases detected with FDG PET as part of the same PET/CT examination. Radiology. 2005;237:627-34.